Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cholangiocarcinoma: early-phase trial registry
36 of 61 indexed Cholangiocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #232 of 28,707 conditions by registered trial count.
61 US clinical trials · 36 currently recruiting · #232 of 28,707 conditions by registered trial count
Cholangiocarcinoma: 61 US clinical trials tracked, 36 recruiting.
Cholangiocarcinoma is the subject of 61 registered US clinical trials on ClinicalTrials.gov, 36 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 38 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.
Enrollment posture brief
Registry condition cholangiocarcinoma
OPEN 36 | RECR 59% | LATE 3 | EARLY 38 | RANK #232 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Meningioma (59% recruiting · 22 trials)
Cholangiocarcinoma lists 36 open slots (59% of 61 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cholangiocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cholangiocarcinoma is recruiting above its size-band peers.
36 of 61 indexed trials (59%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cholangiocarcinoma trials is spread across many organizations.
National Cancer Institute (NCI) accounts for 6 of 61 trials (9.8%). 46 distinct sponsors appear on at least one study for this condition label.
-
Typical Cholangiocarcinoma enrolment sits around 110 participants.
Median target enrolment is 110 among the 61 trials that report a genuine target (sentinel values excluded). 28 of those (45.9%) plan for fewer than 100 participants.
-
Cholangiocarcinoma research is mostly interventional.
51 interventional and 10 observational studies make up this index (83.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
61 total, page 1 of 2
Biobank for Cholestatic Liver Diseases.
Mayo Clinic
NCT03445585
Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
National Cancer Institute (NCI)
NCT01915225
Molecular Epidemiology of Biliary Tree Cancers
M.D. Anderson Cancer Center
NCT05179486
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
City of Hope Medical Center
NCT07224750
Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Washington University School of Medicine
NCT06340646
High Volume Washing of the Abdomen in Increasing Survival After Surgery in Patients With Pancreatic Cancer That Can Be Removed by Surgery
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT02757859
National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
National Cancer Institute (NCI)
NCT04145141
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Mohamed Abdel-Rahman
NCT04792463
An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
City of Hope Medical Center
NCT06342414
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
TargetCancer Foundation
NCT04504604
The Dragon PLC Trial (DRAGON-PLC)
Maastricht University
NCT06914648
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Cancer Institute (NCI)
NCT06503146
Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients
Mayo Clinic
NCT04753996
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Eli Lilly and Company
NCT07213791
Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
Washington University School of Medicine
NCT06910670
BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours
Bold Therapeutics
NCT04421820
Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma
TransThera Sciences (Nanjing)
NCT05948475
A Study of MGC028 in Participants With Advanced Solid Tumors
MacroGenics
NCT06723236
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Cogent Biosciences
NCT06777316
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
M.D. Anderson Cancer Center
NCT02379377
Targeted Navigation in Hepatocellular Carcinoma (HCC)
University of Miami
NCT06260943
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
Apollo Therapeutics
NCT06399757
Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Genfit
NCT05874414
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
National Cancer Institute (NCI)
NCT05286814
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
Massachusetts General Hospital
NCT06302621
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
Udai Kammula
NCT03801083
HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer
Montefiore Medical Center
NCT06899152
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Nataliya Uboha
NCT06048133
Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers
National Cancer Institute (NCI)
NCT04645160
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
NCT07118176
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Beth Israel Deaconess Medical Center
NCT05655949
Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer
Case Comprehensive Cancer Center
NCT07146646
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
M.D. Anderson Cancer Center
NCT05967182
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Rigel Pharmaceuticals
NCT07486713
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
University of California, Irvine
NCT05497531
Chemoimmunotherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherapy in Advanced Biliary Tract Cancer
University of Maryland, Baltimore
NCT06546969
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Hoffmann-La Roche
NCT02568267
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
NCT04521686
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
NGM Biopharmaceuticals
NCT04913337
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Compass Therapeutics
NCT05506943
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Toray Industries
NCT03872947
A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors
Lisata Therapeutics
NCT05712356
Domvanalimab and Zimberelimab in Advanced Liver Cancers
University of Texas Southwestern Medical Center
NCT05724563
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
TCR2 Therapeutics
NCT03907852
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Seagen, a wholly owned subsidiary of Pfizer
NCT04430738
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
NCT02626312
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Jonsson Comprehensive Cancer Center
NCT04459273
Senior Adult Hepatobiliary Prehab Study
H. Lee Moffitt Cancer Center and Research Institute
NCT05921552
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Elevar Therapeutics
NCT04526106
Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)
City of Hope Medical Center
NCT06381648
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 20 |
| Phase 2 | 18 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Cholangiocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cholangiocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cholangiocarcinoma page
61 registered trials, 36 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 36 Cholangiocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Cholangiocarcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cholangiocarcinoma condition card totals 61 registered trials; most-linked intervention Gemcitabine; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.